50. A pharmaceutical composition comprising:

a binding agent that recognizes an epitope recognized by an antibody selected from any one of claims 1-29; and;

a pharmaceutically acceptable excipient.

51. A pharmaceutical composition comprising:

a fragment of an antibody selected from any one of claims 1-29, wherein the fragment retains the antigen binding activity of the whole antibody; and

a pharmaceutically acceptable excipient.

52. The pharmaceutical composition of any one of claims 49-51, further comprising at least one additional antiviral agent.

53. ~~A~~ Use of a ~~method of treating a subject, the method comprising steps of:~~ ~~administering to a subject suffering from or susceptible to influenza infection a~~ therapeutically effective amount of the antibody, binding agent or pharmaceutical composition of any one of claims 1-29, 30-45, and 49-52, in the manufacture of a medicament for treating a subject suffering from or susceptible to influenza infection.

54. A kit comprising:

at least one antibody of any one of claims 1-29;

a syringe, needle, or applicator for administration of the at least one antibody to a subject; and

instructions for use.

55. A kit comprising:

at least one binding agent of any one of claims 30-45;

a syringe, needle, or applicator for administration of the at least one antibody to a subject; and

instructions for use.